A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH

BACKGROUND: Visceral leishmaniasis (VL or kala azar) is the most serious form of human leishmaniasis, responsible for over 20,000 deaths annually, and post kala azar dermal leishmaniasis (PKDL) is a stigmatizing skin condition that often occurs in patients after successful treatment for VL. Lack of...

Descripción completa

Detalles Bibliográficos
Autores principales: Osman, Mohamed, Mistry, Anoop, Keding, Ada, Gabe, Rhian, Cook, Elizabeth, Forrester, Sarah, Wiggins, Rebecca, Di Marco, Stefania, Colloca, Stefano, Siani, Loredana, Cortese, Riccardo, Smith, Deborah F., Aebischer, Toni, Kaye, Paul M., Lacey, Charles J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5443534/
https://www.ncbi.nlm.nih.gov/pubmed/28498840
http://dx.doi.org/10.1371/journal.pntd.0005527

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5443534/
https://www.ncbi.nlm.nih.gov/pubmed/28498840
http://dx.doi.org/10.1371/journal.pntd.0005527

Ejemplares similares